Navid Sobhi

Dr. Navid Sobhi

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2025 in Journal of Diabetes & Metabolic Disorders
Verified
Journal Article
Open access
PDF file
Navid SobhiNavid Sobhi
Navid Sobhi
YSYasin Sadeghi-Bazargani
Yasin Sadeghi-Bazargani
MMMajid Mirzaei
Majid Mirzaei
MAMirsaeed Abdollahi
Mirsaeed Abdollahi
Ali JafarizadehAli Jafarizadeh
Ali Jafarizadeh
U Rajendra AcharyaU Rajendra Acharya
U Rajendra Acharya
Background: Diabetes mellitus (DM) increases the risk of vascular complications, and retinal vasculature imaging serves as a valuable indicator of both microvascular and macrovascular health. Moreover, artificial intelligence (AI)-enabled systems developed for high-throughput detection of diabetic retinopathy (DR) using digitized retinal images have become clinically adopted. This study reviews AI applications using retinal images for DM-related complications, highlighting advancements beyond DR screening, diagnosis, and prognosis, and addresses implementation challenges, such as ethics, data privacy, equitable access, and explainability. Methods: We conducted a thorough literature search across several databases, including PubMed, Scopus, and Web of Science, focusing on studies involving diabetes, the retina, and artificial intelligence. We reviewed the original research based on their methodology, AI algorithms, data processing techniques, and validation procedures to ensure a detailed analysis of AI applications in diabetic retinal imaging. Results: Retinal images can be used to diagnose DM complications including DR, neuropathy, nephropathy, and atherosclerotic cardiovascular disease, as well as to predict the risk of cardiovascular events. Beyond DR screening, AI integration also offers significant potential to address the challenges in the comprehensive care of patients with DM. Conclusion: With the ability to evaluate the patient’s health status in relation to DM complications as well as risk prognostication of future cardiovascular complications, AI-assisted retinal image analysis has the potential to become a central tool for modern personalized medicine in patients with DM.
3

29 March 2025 in Artificial Intelligence Review
Verified
Journal Article
Open access
PDF file
Ali JafarizadehAli Jafarizadeh
Ali Jafarizadeh
SMShadi Farabi Maleki
Shadi Farabi Maleki
PPParnia Pouya
Parnia Pouya
Navid SobhiNavid Sobhi
Navid Sobhi
MAMirsaeed Abdollahi
Mirsaeed Abdollahi
U Rajendra AcharyaU Rajendra Acharya
U Rajendra Acharya
Retinopathy of prematurity (ROP) is a severe condition affecting premature infants, leading to abnormal retinal blood vessel growth, retinal detachment, and potential blindness. While semi-automated systems have been used in the past to diagnose ROP-related plus disease by quantifying retinal vessel features, traditional machine learning (ML) models face challenges like accuracy and overfitting. Recent advancements in deep learning (DL), especially convolutional neural networks (CNNs), have significantly improved ROP detection and classification. The i-ROP deep learning (i-ROP-DL) system also shows promise in detecting plus disease, offering reliable ROP diagnosis potential. This research comprehensively examines the contemporary progress and challenges associated with using retinal imaging and artificial intelligence (AI) to detect ROP, offering valuable insights that can guide further investigation in this domain. Based on 84 original studies in this field (out of 2025 studies that were comprehensively reviewed), we concluded that traditional methods for ROP diagnosis suffer from subjectivity and manual analysis, leading to inconsistent clinical decisions. AI holds great promise for improving ROP management. This review explores AI’s potential in ROP detection, classification, diagnosis, and prognosis.
3

9 October 2024 in WIREs Data Mining and Knowledge Discovery
Verified
Journal Article
Open access
MAMirsaeed Abdollahi
Mirsaeed Abdollahi
Ali JafarizadehAli Jafarizadeh
Ali Jafarizadeh
AGAmirhosein Ghafouri‐Asbagh
Amirhosein Ghafouri‐Asbagh
Navid SobhiNavid Sobhi
Navid Sobhi
KPKeysan Pourmoghtader
Keysan Pourmoghtader
U Rajendra AcharyaU Rajendra Acharya
U Rajendra Acharya
Cardiovascular diseases (CVDs) are the leading cause of death globally. The use of artificial intelligence (AI) methods—in particular, deep learning (DL)—has been on the rise lately for the analysis of different CVD‐related topics. The use of fundus images and optical coherence tomography angiography (OCTA) in the diagnosis of retinal diseases has also been extensively studied. To better understand heart function and anticipate changes based on microvascular characteristics and function, researchers are currently exploring the integration of AI with noninvasive retinal scanning. There is great potential to reduce the number of cardiovascular events and the financial strain on healthcare systems by utilizing AI‐assisted early detection and prediction of cardiovascular diseases on a large scale. A comprehensive search was conducted across various databases, including PubMed, Medline, Google Scholar, Scopus, Web of Sciences, IEEE Xplore, and ACM Digital Library, using specific keywords related to cardiovascular diseases and AI. The study included 87 English‐language publications selected for relevance, and additional references were considered. This article provides an overview of the recent developments and difficulties in using AI and retinal imaging to diagnose cardiovascular diseases. It provides insights for further exploration in this field. Researchers are trying to develop precise disease prognosis patterns in response to the aging population and the growing global burden of CVD. AI and DL are revolutionizing healthcare by potentially diagnosing multiple CVDs from a single retinal image. However, swifter adoption of these technologies in healthcare systems is required.This article is categorized under: Application Areas > Health Care Technologies > Artificial Intelligence
3

4 June 2024 in Cancers
Verified
Journal Article
Open access
PDF file
Hamidreza AshayeriHamidreza Ashayeri
Hamidreza Ashayeri
Navid SobhiNavid Sobhi
Navid Sobhi
Pawel PlawiakPawel Plawiak
Pawel Plawiak
Siamak PedrammehrSiamak Pedrammehr
Siamak Pedrammehr
RARoohallah Alizadehsani
Roohallah Alizadehsani
Ali JafarizadehAli Jafarizadeh
Ali Jafarizadeh
Artificial intelligence (AI), encompassing machine learning (ML) and deep learning (DL), has revolutionized medical research, facilitating advancements in drug discovery and cancer diagnosis. ML identifies patterns in data, while DL employs neural networks for intricate processing. Predictive modeling challenges, such as data labeling, are addressed by transfer learning (TL), leveraging pre-existing models for faster training. TL shows potential in genetic research, improving tasks like gene expression analysis, mutation detection, genetic syndrome recognition, and genotype–phenotype association. This review explores the role of TL in overcoming challenges in mutation detection, genetic syndrome detection, gene expression, or phenotype–genotype association. TL has shown effectiveness in various aspects of genetic research. TL enhances the accuracy and efficiency of mutation detection, aiding in the identification of genetic abnormalities. TL can improve the diagnostic accuracy of syndrome-related genetic patterns. Moreover, TL plays a crucial role in gene expression analysis in order to accurately predict gene expression levels and their interactions. Additionally, TL enhances phenotype–genotype association studies by leveraging pre-trained models. In conclusion, TL enhances AI efficiency by improving mutation prediction, gene expression analysis, and genetic syndrome detection. Future studies should focus on increasing domain similarities, expanding databases, and incorporating clinical data for better predictions.
3

1 March 2024 in Current Alzheimer Research
Verified
Journal Article
Closed access
PDF file
SMShadi Farabi Maleki
Shadi Farabi Maleki
MYMilad Yousefi
Milad Yousefi
Navid SobhiNavid Sobhi
Navid Sobhi
Ali JafarizadehAli Jafarizadeh
Ali Jafarizadeh
RARoohallah Alizadehsani
Roohallah Alizadehsani
Juan M. Górriz SáezJuan M. Górriz Sáez
Juan M. Górriz Sáez
: As the world's population ages, Alzheimer's disease is currently the seventh most common cause of death globally; the burden is anticipated to increase, especially among middle-class and elderly persons. Artificial intelligence-based algorithms that work well in hospital environments can be used to identify Alzheimer's disease. A number of databases were searched for English-language articles published up until March 1, 2024, that examined the relationships between artificial intelligence techniques, eye movements, and Alzheimer's disease. A novel non-invasive method called eye movement analysis may be able to reflect cognitive processes and identify anomalies in Alzheimer's disease. Artificial intelligence, particularly deep learning, and machine learning, is required to enhance Alzheimer's disease detection using eye movement data. One sort of deep learning technique that shows promise is convolutional neural networks, which need further data for precise classification. Nonetheless, machine learning models showed a high degree of accuracy in this context. Artificial intelligence-driven eye movement analysis holds promise for enhancing clinical evaluations, enabling tailored treatment, and fostering the development of early and precise Alzheimer's disease diagnosis. A combination of artificial intelligence-based systems and eye movement analysis can provide a window for early and non-invasive diagnosis of Alzheimer's disease. Despite ongoing difficulties with early Alzheimer's disease detection, this presents a novel strategy that may have consequences for clinical evaluations and customized medication to improve early and accurate diagnosis.
3

28 May 2024 in Seminars in Ophthalmology
Verified
Journal Article
Closed access
Navid SobhiNavid Sobhi
Navid Sobhi
MAMirsaeed Abdollahi
Mirsaeed Abdollahi
AAAli Arman
Ali Arman
AMAta Mahmoodpoor
Ata Mahmoodpoor
Ali JafarizadehAli Jafarizadeh
Ali Jafarizadeh
Methanol-induced optic neuropathy (MION) represents a critical public health issue, particularly prevalent in lower socioeconomic populations and regions with restricted alcohol access. MION, characterized by irreversible visual impairment, arises from the toxic metabolization of methanol into formaldehyde and formic acid, leading to mitochondrial oxidative phosphorylation inhibition, oxidative stress, and subsequent neurotoxicity. The pathogenesis involves axonal and glial cell degeneration within the optic nerve and potential retinal damage. Despite advancements in therapeutic interventions, a significant proportion of affected individuals endure persistent visual sequelae. The study comprehensively investigates the pathophysiology of MION, encompassing the absorption and metabolism of methanol, subsequent systemic effects, and ocular impacts. Histopathological changes, including alterations in retinal layers and proteins, Müller cell dysfunction, and visual symptoms, are meticulously examined to provide insights into the disease mechanism. Furthermore, preventive measures and public health perspectives are discussed to highlight the importance of awareness and intervention strategies. Therapeutic approaches, such as decontamination procedures, ethanol and fomepizole administration, hemodialysis, intravenous fluids, electrolyte balance management, nutritional therapy, corticosteroid therapy, and erythropoietin (EPO) treatment, are evaluated for their efficacy in managing MION. This comprehensive review underscores the need for increased awareness, improved diagnostic strategies, and more effective treatments to mitigate the impact of MION on global health.
3